How to provide thromboprophylaxis (thrombosis prevention) for a female patient in the Intensive Care Unit (ICU) with shock, sepsis, pneumonia, stage 5 Chronic Kidney Disease (CKD) on Hemodialysis (HD), and experiencing hematemesis (gastrointestinal bleeding) on a Nasogastric Tube (NGT)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 20, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Thromboprophylaxis Management in ICU Patient with Septic Shock, CKD 5 on HD, and Active GI Bleeding

This patient should receive mechanical thromboprophylaxis only (intermittent pneumatic compression devices) until the hematemesis resolves, at which point unfractionated heparin (UFH) 5,000 units subcutaneously every 8-12 hours should be initiated given her severe renal impairment. 1

Immediate Management: Mechanical Prophylaxis Only

  • Active gastrointestinal bleeding (hematemesis) is an absolute contraindication to pharmacologic thromboprophylaxis and requires mechanical prophylaxis as the sole intervention until bleeding resolves 1, 2

  • Initiate intermittent pneumatic compression devices immediately, as these have proven efficacy and are specifically recommended when anticoagulation is contraindicated 1, 3

  • Graduated compression stockings can be added unless contraindicated by peripheral vascular disease or severe edema 1

When to Transition to Pharmacologic Prophylaxis

Monitor daily for resolution of bleeding risk factors - once hematemesis stops and hemoglobin stabilizes without transfusion requirements, pharmacologic prophylaxis should be initiated 1

Critical Decision Point: Choice of Agent

Given this patient's CKD 5 on hemodialysis (creatinine clearance <30 mL/min), the choice of anticoagulant is crucial:

  • Unfractionated heparin (UFH) 5,000 units subcutaneously every 8-12 hours is the preferred agent for patients with severe renal impairment, as it does not accumulate and does not require renal clearance 1, 3

  • LMWH is generally preferred over UFH in septic patients with normal renal function 1, 3, but this patient's CKD 5 status makes UFH the safer choice

  • If dalteparin is available, it can be used as an alternative LMWH with low renal metabolism, though UFH remains the gold standard in this setting 1

Monitoring Requirements

  • Check platelet count before initiating any heparin therapy and monitor every 2-3 days for heparin-induced thrombocytopenia (HIT), which occurs in up to 30% of heparin-treated patients 2

  • If platelet count falls below 100,000/mm³ or if new thrombosis develops, immediately discontinue heparin and evaluate for HIT/HITT 2

  • Monitor for recurrent bleeding daily - check hemoglobin, observe NGT output, and assess for melena 4, 5

  • Coagulation monitoring (aPTT) is not required for prophylactic-dose UFH 2

Combination Therapy After Bleeding Resolves

Once pharmacologic prophylaxis is initiated, continue mechanical prophylaxis concurrently - the combination of pharmacologic and mechanical prophylaxis is recommended for critically ill septic patients whenever possible 1, 3

Special Considerations for This Patient

Septic Shock Context

  • This patient has severe sepsis/septic shock, which carries a strong recommendation for VTE prophylaxis due to high thrombotic risk from immobility, inflammation, and critical illness 1, 3

  • Septic patients have significantly elevated VTE risk, with studies showing DVT incidence of 26-29% without prophylaxis versus 4-13% with prophylaxis 1, 3

Hemodialysis Considerations

  • Patients on chronic hemodialysis have better ICU outcomes than those with acute kidney injury requiring new dialysis, suggesting dialysis dependence alone should not influence aggressive VTE prevention 6

  • During hemodialysis sessions, the patient will receive systemic heparinization, which provides some additional thromboprophylaxis 2

Active Bleeding Risk Stratification

  • Hematemesis represents a major bleeding contraindication that must be respected 2

  • The FDA label explicitly warns against heparin use in "uncontrolled active bleeding state" and lists "ulcerative lesions and continuous tube drainage of the stomach or small intestine" as conditions requiring caution 2

  • However, the Surviving Sepsis Campaign acknowledges that when bleeding risk decreases, pharmacologic prophylaxis should be started 1

Common Pitfalls to Avoid

  • Do not use LMWH in this patient - despite being preferred in general septic populations, severe renal impairment (CKD 5) causes LMWH accumulation and increased bleeding risk 1

  • Do not delay mechanical prophylaxis - waiting for bleeding to resolve before starting any prophylaxis increases VTE risk unnecessarily 1

  • Do not use prophylactic anticoagulation while active hematemesis continues - the bleeding risk outweighs thrombotic risk during active hemorrhage 2

  • Do not forget stress ulcer prophylaxis - this patient has multiple risk factors (mechanical ventilation implied by ICU status, septic shock, coagulopathy risk) and should receive proton pump inhibitor or H2-receptor antagonist 1, 4, 5

Reassessment Timeline

  • Daily evaluation of bleeding status - assess NGT output, hemoglobin trends, and hemodynamic stability 4, 5

  • Initiate UFH within 24-48 hours of bleeding cessation if no contraindications remain 1

  • Continue prophylaxis throughout ICU stay and until patient is fully ambulatory 1, 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Heparin for DVT Prophylaxis in Sepsis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Gastrointestinal Prophylaxis in High-Risk Patients

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Development of Stress-Related Gastric Ulcers in Critically Ill Patients

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Outcomes of chronic hemodialysis patients in the intensive care unit.

Critical care research and practice, 2013

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.